Blood Patents (Class 530/829)
  • Patent number: 8729244
    Abstract: The invention relates to a method for purifying factor B, comprising the steps consisting in: (i) obtaining a blood plasma fraction containing factor B; (ii) subjecting the fraction obtained in step (i) to a heparin-like affinity chromatography; (iii) subjecting the factor B-enriched fraction obtained in step (ii) to a cation exchange chromatography; (iv) subjecting the factor B-enriched fraction obtained in step (iii) to an anion exchange chromatography, (v) eluting the factor B.
    Type: Grant
    Filed: November 15, 2010
    Date of Patent: May 20, 2014
    Assignee: Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventor: Michel Poulle
  • Patent number: 8680069
    Abstract: The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and/or activity.
    Type: Grant
    Filed: May 18, 2013
    Date of Patent: March 25, 2014
    Assignee: Moderna Therapeutics, Inc.
    Inventors: Antonin de Fougerolles, Kristy M. Wood, Sayda M. Elbashir, Jason P. Schrum
  • Patent number: 8673335
    Abstract: Compositions and methods for sealing, coating and adhering tissues are provided that utilize a polymeric system comprising at least a Polymer and a crosslinking agent; and, optionally, (i) a Gelation Disrupting Agent, (ii) an Augmentative Polymer or Monomer, (iii) an Adjunct Compound (iv) an Antimicrobial Agent (v) an Adhesion Enhancer, (vi) a Crosslink Augmentating Agent or any combination thereof. Additionally, a Therapeutic Agent may be incorporated.
    Type: Grant
    Filed: September 13, 2007
    Date of Patent: March 18, 2014
    Assignee: Southeastern Medical Technologies, LLC
    Inventors: Curtis E. Jones, John P. Kennedy
  • Patent number: 8372800
    Abstract: An albumin-free Factor VIII formulation comprising: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent. Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent. In a further embodiment, the formulation can comprise: 300 mM to 500 mM NaCl; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; and a buffering agent.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: February 12, 2013
    Assignees: Baxter International Inc., University of Connecticut
    Inventors: Marc Besman, Erik Bjornson, Feroz Jameel, Ramesh Kashi, Michael Pikal, Serguei Tchessalov, John Carpenter
  • Patent number: 8084224
    Abstract: A method to facilitate recovery troponin I and/or troponin T from a sample comprising addition of troponin C to the sample or to a surface from which the troponin I and/or troponin T are recovered.
    Type: Grant
    Filed: April 5, 2010
    Date of Patent: December 27, 2011
    Assignee: Alere San Diego, Inc.
    Inventors: Kenneth F. Buechler, Paul H. McPherson
  • Patent number: 8058226
    Abstract: A Factor VIII composition formulated without albumin, comprising the following formulation excipients in addition to Factor VIII: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8. Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8.
    Type: Grant
    Filed: June 18, 2007
    Date of Patent: November 15, 2011
    Assignees: Baxter International Inc., University of Connecticut
    Inventors: Marc Besman, Erik Bjornson, Feroz Jameel, Ramesh Kashi, Michael Pikal, Serguei Tchessalov, John Carpenter
  • Patent number: 7521417
    Abstract: A process is disclosed for the preparation of an essentially tetramer-free, substantially stroma-free, polymerized, pyridoxylated hemoglobin. Also disclosed is an essentially tetramer-free, substantially stroma-free, polymerized, pyridoxylated hemoglobin product capable of being infused into human patients in an amount of up to about 5 liters.
    Type: Grant
    Filed: January 10, 2008
    Date of Patent: April 21, 2009
    Assignee: Northfield Laboratories, Inc.
    Inventors: Richard E. DeWoskin, Marc D. Doubleday
  • Patent number: 7479540
    Abstract: Adipomodulin (a light chain molecule) and related molecules and methods useful in the treatment of obesity and obesity-related disorders.
    Type: Grant
    Filed: April 5, 2005
    Date of Patent: January 20, 2009
    Inventors: Chandan Prasad, Julio E. Figueroa, II, Parakat Vijayagopal
  • Patent number: 7411044
    Abstract: A substantially tetramer free hemoglobin solution and a method for producing a substantially tetramer free hemoglobin solution. The method includes polymerizing a solution of hemoglobin, treating the polymerized hemoglobin solution to partially degrade the polymer to tetramer and removing tetramer from the hemoglobin solution.
    Type: Grant
    Filed: August 24, 2006
    Date of Patent: August 12, 2008
    Assignee: Northfield Laboratories, Inc.
    Inventors: Anthony Avella, Richard DeWoskin, Marc Doubleday
  • Patent number: 7291592
    Abstract: Methods for treating a mammal suffering from massive blood loss comprising administering to the mammal a polymerized hemoglobin solution.
    Type: Grant
    Filed: October 3, 2003
    Date of Patent: November 6, 2007
    Assignee: Northfield Laboratories, Inc.
    Inventors: Steven Gould, Richard DeWoskin, Marc Doubleday, George Hides
  • Patent number: 7247707
    Abstract: A Factor VIII composition formulated without albumin, comprising the following formulation excipients in addition to Factor VIII: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8. Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8.
    Type: Grant
    Filed: May 15, 2006
    Date of Patent: July 24, 2007
    Assignees: Baxter International Inc., University of Connecticut
    Inventors: Marc Besman, Erik Bjornson, Feroz Jameel, Ramesh Kashi, Michael Pikal, Serguei Tchessalov, John Carpenter
  • Patent number: 7135553
    Abstract: A substantially tetramer free hemoglobin solution and a method for producing a substantially tetramer free hemoglobin solution. The method includes polymerizing a solution of hemoglobin, treating the polymerized hemoglobin solution to partially degrade the polymer to tetramer and removing tetramer from the hemoglobin solution.
    Type: Grant
    Filed: January 29, 2004
    Date of Patent: November 14, 2006
    Assignee: Northfield Laboratories, Inc.
    Inventors: Anthony Avella, Richard DeWoskin, Marc Doubleday
  • Patent number: 7115710
    Abstract: The present invention relates to PTP05 polypeptides and PTP10 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for PTP05 and/or PTP10 related diseases or conditions characterized by an abnormal interaction between a PTP05 polypeptide and a PTP05 binding partner and/or a PTP10 polypeptide and a PTP10 binding partner.
    Type: Grant
    Filed: June 10, 1998
    Date of Patent: October 3, 2006
    Assignee: Sugen, Inc.
    Inventors: Gregory D. Plowman, Bahija Jallal
  • Patent number: 7101846
    Abstract: Compositions, and methods of use thereof, for use as blood substitute products comprise aqueous mixtures of oxygen-carrying and non-oxygen carrying plasma expanders and methods for the use thereof. The oxygen-carrying component may consist of any hemoglobin-based oxygen carrier, while the non-oxygen carrying plasma expander my consist of any suitable diluent.
    Type: Grant
    Filed: August 11, 2004
    Date of Patent: September 5, 2006
    Assignee: The Regents of the University of California
    Inventor: Robert M. Winslow
  • Patent number: 7101557
    Abstract: The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising coagulant-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutic drugs, targeted immunotoxins, targeted coaguligands, and/or in combination with Factor VIIa (FVIIa) or FVIIa activators.
    Type: Grant
    Filed: February 27, 2003
    Date of Patent: September 5, 2006
    Assignee: Board of Regents The University of Texas System
    Inventors: Philip E. Thorpe, Steven W. King, Boning Gao
  • Patent number: 7087723
    Abstract: A Factor VIII composition formulated without albumin, comprising the following formulation excipients in addition to Factor VIII: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8. Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8.
    Type: Grant
    Filed: July 1, 2003
    Date of Patent: August 8, 2006
    Assignees: Baxter International Inc., University of Connecticut
    Inventors: Marc Besman, Erik Bjornson, Feroz Jameel, Ramesh Kashi, Michael Pikal, Serguei Tchessalov, John Carpenter
  • Patent number: 7087719
    Abstract: The present invention relates to the purification and production of human albumin from various sources through crystallization and repeated crystallization. Basic features of the invented process include providing specific reaction conditions and precipitating reagents to maximize albumin crystallization. Solubility diagrams are utilized as the basis for process control of the invented method. The current invention specifically controls phosphate concentration, pH and temperature to precisely guide crystallization kinetics and crystal yield.
    Type: Grant
    Filed: November 19, 2002
    Date of Patent: August 8, 2006
    Assignee: GTC Biotherapeutics, Inc.
    Inventors: Kalevi Visuri, Sinikka Uotila, Scott P. Fulton, Daniel E. Couto
  • Patent number: 6986984
    Abstract: Red blood cells are purified by defibrinating whole blood and then filtering the defibrinated whole blood, whereby at least a portion of a plasma component is separated from the red blood cells to form a suspension of red blood cells, thereby purifying the red blood cells. Whole blood is defibrinated by, for example, using a chemical coagulating agent or mechanical agitation. Separation of the plasma component from red blood cells can be completed by, for example, diafiltration. The suspension of red blood cells can then be employed to produce a hemoglobin-based oxygen carrier.
    Type: Grant
    Filed: November 26, 2002
    Date of Patent: January 17, 2006
    Assignee: Biopure Corporation
    Inventors: Maria S. Gawryl, Robert A. Houtchens, William R. Light
  • Patent number: 6936423
    Abstract: Lethal Toxin Neutralizing Factor has been isolated in purity from opossum serum by high pressure liquid chromatography (HPLC) fractionation. The amino acid sequence from the N-terminal for the first fifteen amino acids of LTNF-n is: Leu Lys Ala Met Asp Pro Thr Pro Pro Leu Trp Ile Lys Thr Glu. Antibodies to LTNF-n and synthetic peptides consisting of fifteen, ten and five amino acids from the N-terminal of the above sequence, designated as LTNF-15, LTNF-10 and LTNF-5 were produced by immunizing Balb/C mice to produce Anti-LTNF-n, Anti-LTNF-15, Anti-LTNF-10 and Anti-LTNF-5. The anti LTNF-n, anti-LTNF-15, anti-LTNF-10 and anti-LTNF-5 react immunologically with all types of toxins derived from animal, plant and bacteria and can be assayed by immunological in vitro test such as ELISA tests. Anti-LTNFs react roughly proportional to lethal dose of biological toxins under in vitro immunological ELISA test similar to the mouse bioassay test.
    Type: Grant
    Filed: April 27, 1999
    Date of Patent: August 30, 2005
    Inventors: Binie V. Lipps, Frederick W. Lipps
  • Patent number: 6884773
    Abstract: Diseases which can be ameliorated by delivery of NO to tissues affected by the disease can be treated by administration of nitrosyl-heme-containing donors of NO, including nitrosylhemoglobin. Nitrosylhemoglobin can be made by the reaction of NO with hemoglobin under certain conditions in which the NO:hemoglobin ratio is critical, and is converted to SNO-Hb under physiological conditions.
    Type: Grant
    Filed: February 6, 1997
    Date of Patent: April 26, 2005
    Assignee: Duke University
    Inventors: Jonathan S. Stamler, Andrew J. Gow
  • Patent number: 6872808
    Abstract: Proteins which have activity as anticoagulants and/or serine protease inhibitors and have at least one NAP domain and are described. Certain of these proteins have factor Xa inhibitory activity and others have activity as inhibitors of factor VIIa/TF. These proteins can be isolated from natural sources as nematodes, chemically synthesized or made by recombinant methods using various DNA expression systems.
    Type: Grant
    Filed: February 4, 2000
    Date of Patent: March 29, 2005
    Assignee: Corvas International, Inc.
    Inventors: George Phillip Vlasuk, Patrick Eric Hugo Stanssens, Joris Hilda Lieven Messens, Marc Josef Lauwereys, Yves Rene LaRoche, Laurent Stephane Jespers, Yannick Georges Jozef Gansemans, Matthew Moyle, Peter W. Bergum
  • Patent number: 6855691
    Abstract: Nitric oxide (NO) interacts with hemoglobin (Hb) at its metal centers, whereas S-nitrosothiols (RSNOs) can donate the NO group to ?93 cysteine residues, thereby shielding the NO functionality from heme inactivation. S-nitrosylation of Hb is under the allosteric control of oxygen and the oxidation state of heme. NO group release from S-nitrosohemoglobin (SNO-Hb) is further facilitated by intracellular low molecular weight thiols, forming RSNOs which can be exported from the erythrocyte to regulate blood pressure. Hence, a dynamic cycle is established in which S-nitrosylation of Hb is initiated in the lung following oxygenation of red blood cells and is completed by SNO-Hb metabolism during arterial-venous transit. SNO-Hb can be formed by reaction of Hb with S-nitrosothiol. This procedure avoids oxidation of the heme.
    Type: Grant
    Filed: March 15, 1996
    Date of Patent: February 15, 2005
    Assignee: Duke University
    Inventor: Jonathan S. Stamler
  • Patent number: 6770278
    Abstract: The invention is directed to methods of using Ig compositions to prevent and/or treat humans, livestock and/or domesticated animals suffering from stress induced respiratory disorders. The Ig composition comprises a concentrated amount of one or more immunoglobulins selected from the group consisting of alpha, beta, and gamma globulins. Preferably, the Ig composition comprises other antibodies identified as providing an immune response and/or immune factors such as complement and transfer factors. The Ig composition preferably includes immunoglobulins specific to a variety of antigens. In a preferred method, an equine Ig composition is used to treat exercise induced pulmonary hemorrhage in horses.
    Type: Grant
    Filed: June 2, 2000
    Date of Patent: August 3, 2004
    Assignee: Central Biomedia, Inc.
    Inventor: William G. Skelly
  • Patent number: 6686332
    Abstract: The present invention provides methods of treating adverse physiological effects associated with depressed reticuloendothelial system function comprising administering to a subject suffering from depressed reticuloendothelial system function an effective amount of a BPI protein product.
    Type: Grant
    Filed: October 12, 2000
    Date of Patent: February 3, 2004
    Assignee: Xoma Corporation
    Inventors: Paul A. M. van Leeuwan, Marja A. Boermeester
  • Patent number: 6627193
    Abstract: Methods for controlling blood coagulation, and suitable pharmaceutical compositions that include a polypeptide that enhances the anticoagulation process (or inhibitors thereof for reversing the anticoagulation process) are provided.
    Type: Grant
    Filed: January 13, 2000
    Date of Patent: September 30, 2003
    Assignee: University of Georgia Research Foundation, Inc.
    Inventors: James Travis, Takahisa Imamura, Jan Potempa
  • Patent number: 6627404
    Abstract: A method to facilitate recovery troponin I and/or troponin T from a sample comprising addition of troponin C to the sample or to a surface from which the troponin I and/or troponin T are recovered.
    Type: Grant
    Filed: December 18, 1996
    Date of Patent: September 30, 2003
    Assignee: Biosite, Inc.
    Inventors: Kenneth F. Buechler, Paul H. McPherson
  • Patent number: 6599881
    Abstract: Antithrombotic materials and methods are provided for the treatment of thrombotic disorders, in which therapeutically effective amounts of BPI protein products are administered.
    Type: Grant
    Filed: July 6, 2000
    Date of Patent: July 29, 2003
    Assignee: Xoma Corporation
    Inventors: Mark L. White, William Steve Ammons
  • Patent number: 6596691
    Abstract: Methods and materials for the treatment of human meningococcemia are provided in which therapeutically effective amounts of BPI protein products are administered.
    Type: Grant
    Filed: November 30, 2000
    Date of Patent: July 22, 2003
    Assignee: XOMA Corporation
    Inventors: Brett P. Giroir, Patrick J. Scannon
  • Patent number: 6586573
    Abstract: A Factor VIII composition formulated without albumin, comprising the following formulation excipients in addition to Factor VIII: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8. Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8.
    Type: Grant
    Filed: February 22, 2000
    Date of Patent: July 1, 2003
    Assignees: Baxter International Inc., University of Connecticut
    Inventors: Marc Besman, Erik Bjornson, Feroz Jameel, Ramesh Kashi, Michael Pikal, Serguei Tchessalov, John Carpenter
  • Patent number: 6583113
    Abstract: Nitrosylation of proteins and amino acid groups enables selective regulation of protein function, and also endows the proteins and amino acids with additional smooth muscle relaxant and platelet inhibitory capabilities. Thus, the invention relates to novel compounds achieved by nitrosylation of protein thiols. Such compounds include: S-nitroso-t-PA, S-nitroso-cathepsin; S-nitroso-lipoprotein; and S-nitroso-immunoglobulin. The invention also relates to therapeutic use of S-nitroso-protein compounds for regulating protein function, cellular metabolism and effecting vasodilation, platelet inhibition, relaxation of non-vascular smooth muscle, and increasing blood oxygen transport by hemoglobin and myoglobin. The compounds are also used to deliver nitric oxide in its most bioactive form in order to achieve the effects described above, or for in vitro nitrosylation of molecules present in the body.
    Type: Grant
    Filed: April 16, 2001
    Date of Patent: June 24, 2003
    Assignee: Brigham and Women's Hospital
    Inventors: Johnathan Stamler, Joseph Loscalzo
  • Patent number: 6521591
    Abstract: A pharmaceutical composition suitable for enhancing muscular anabolism contains, per daily dose, at least 5 mg of anabolic initiators comprising anabolic growth factors, at least 0.12 g of protein equivalents of anabolic substrates and at least 3 g of anabolic facilitators comprising at least 1 g of creatine or its functional analog. The anabolic initiators may be derived from a non-denatured animal protein, non-denatured being defined as having an F0 of less than 3.0.
    Type: Grant
    Filed: February 10, 2000
    Date of Patent: February 18, 2003
    Assignee: N.V. Nutricia
    Inventors: Rudolf Leonardus Lodewijk Smeets, Robert Johan Joseph Hageman
  • Patent number: 6514701
    Abstract: Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
    Type: Grant
    Filed: July 19, 2000
    Date of Patent: February 4, 2003
    Assignee: The Board of Regents of the University of Oklahoma
    Inventor: H. Anne Pereira
  • Patent number: 6498141
    Abstract: A process is disclosed for the preparation of an essentially tetramer-free, substantially stroma-free, polymerized, pyridoxylated hemoglobin. Also disclosed is an essentially tetramer-free, substantially stroma-free, polymerized, pyridoxylated hemoglobin product capable of being infused into human patients in an amount of up to about 5 liters.
    Type: Grant
    Filed: May 10, 1999
    Date of Patent: December 24, 2002
    Assignee: Northfield Laboratories, Inc.
    Inventors: Richard E. DeWoskin, Marc D. Doubleday
  • Patent number: 6432918
    Abstract: Compositions, and methods of use thereof, for use as blood substitute products comprise aqueous mixtures of oxygen-carrying and non-oxygen carrying plasma expanders and methods for the use thereof. The oxygen-carrying component may consist of any hemoglobin-based oxygen carrier, while the non-oxygen carrying plasma expander my consist of any suitable diluent.
    Type: Grant
    Filed: April 5, 2000
    Date of Patent: August 13, 2002
    Assignee: The Regents of the University of California
    Inventor: Robert M. Winslow
  • Publication number: 20020099174
    Abstract: The present invention relates generally to a method of separating one or more components from a protein mixture. More particularly, this invention is directed to a method of separating one or more components of blood plasma comprising one or more filtration steps using a cellulose-based filter aid. The present invention is useful in the preparation of therapeutics, in particular plasma-based therapeutics for use in humans.
    Type: Application
    Filed: February 2, 1999
    Publication date: July 25, 2002
    Inventors: ANNA JOHNSTON, JEFFERY RAYMOND DAVIES, PETER JAMES TURNER, BRENTON JOHN WILKIE
  • Publication number: 20020099196
    Abstract: The present invention provides a novel polypeptide possessing growth activities on hematopoietic stem cells, a gene encoding the polypeptide and an antibody reacting specifically with the polypeptide, as well as a method for isolating the above gene and a vector for use in the method. According to the present invention, it is possible to elucidate the pathogenesis of various hematopoietic diseases due to abnormalities in hematopoietic stem cells and of bone marrow inhibition, and to diagnose and treat such diseases. According to the present invention, it is also possible to amplify hematopoietic stem cells in vitro for bone marrow transplantation necessary for the treatment of such diseases or improve efficiency of a gene transfer into hematopoietic stem cells for utilizing the gene therapy. The vector and the method of gene isolation developed to isolate the SCGF gene of the invention are applicable to search for other novel genes and able to contribute to the technological progress in genetic engineering.
    Type: Application
    Filed: April 27, 1998
    Publication date: July 25, 2002
    Applicant: KYOWA HAKKO KOGYO CO., LTD. AND ATSUNOBU HIRAOKA
    Inventors: ATSUNOBU HIRAOKA, ATSUSHI SUGIMURA, HIROYUKI MIO
  • Patent number: 6387877
    Abstract: The invention relates to a method of removing endotoxin from preparations of alpha-1-acid glycoprotein (orosomucoid) by contact with a finely divided non-toxic resin such as fumed silica. The invention also relates to a purification process for alpha-1-acid glycoprotein which includes this deprogenation step, and to the depyrogenated product and its clinical uses.
    Type: Grant
    Filed: January 25, 1999
    Date of Patent: May 14, 2002
    Assignee: National Blood Authority
    Inventors: John Edward More, Jacqueline Rott, David Roger Lewin
  • Publication number: 20020025343
    Abstract: A process is disclosed for the preparation of an essentially tetramerfree, substantially stromafree, polymerized, pyridoxylated hemoglobin. Also disclosed is an essentially tetramerfree, substantially stromafree, polymerized, pyridoxylated hemoglobin product capable of being infused into human patients in an amount of up to about 5 liters.
    Type: Application
    Filed: May 10, 1999
    Publication date: February 28, 2002
    Inventors: RICHARD E. DE WOSKIN, MARC D. DOUBLEDAY
  • Patent number: 6340667
    Abstract: The present invention provides compositions useful as antimicrobial agents which include reptilian hemoglobin, the &agr; and &bgr; chains of hemoglobin free of heme, fragments of said proteins or polypeptide fragments thereof and combinations thereof. The compositions exert antimicrobial activity against both bacteria and fungi that is comparable to known antimicrobial peptides from human neutrophils, cathepsin G and azurocidin. Sensitive organisms include Gram-negative bacteria such as Escherichia coli and Pseudomonas aerioginosa, and the fungus Candida albicans. Methods for preparing the compositions also are provided.
    Type: Grant
    Filed: July 14, 1999
    Date of Patent: January 22, 2002
    Assignee: Theragem, Inc.
    Inventors: Brian F. Hoffman, Ofer Binah
  • Patent number: 6337314
    Abstract: The present invention provides compositions useful as antimicrobial agents which include mammalian hemoglobin, the &agr; and &bgr; chains of hemoglobin free of heme, fragments of the &agr; and &bgr; chains that result from cyanogen bromide cleavage of the &agr; and &bgr; chains, and synthetic peptides derived therefrom. The compositions exert antimicrobial activity against both bacteria and fungi that is comparable to known antimicrobial peptides from human neutrophils, cathepsin G and azurocidin. Sensitive organisms include Gram-negative bacteria such as Escherichia coli and Pseudomonas aeruginosa, Gram-positive bacteria such as Staphylococcus aureus and Streptococcus faecalis, and the fungus Candida albicans. Methods for preparing the compositions also are provided.
    Type: Grant
    Filed: July 14, 1999
    Date of Patent: January 8, 2002
    Assignee: Theragem, Inc.
    Inventors: Brian F. Hoffman, Bernard Dubnick
  • Patent number: 6329500
    Abstract: The present invention relates to a composition and method for inhibiting TGF-&bgr; activity. The composition comprises a TGF-&bgr; neutralizing peptide derived from &agr;2-macroglobulin that binds to TGF-&bgr; and inhibits TGF-&bgr; activity.
    Type: Grant
    Filed: May 13, 1999
    Date of Patent: December 11, 2001
    Assignee: University of Virginia Patent Foundation
    Inventors: Donna J. Webb, Steven L. Gonias
  • Patent number: 6320029
    Abstract: The present invention relates to the preparation and use of liquid formulations of plasma proteins, particularly blood coagulation factors. More specifically, the present invention relates to stable liquid formulations of Factor VIII and Factor IX that can be administered by injection or infusion to provide a constant level of the coagulation factor in the blood.
    Type: Grant
    Filed: June 8, 1999
    Date of Patent: November 20, 2001
    Assignees: The American National Red Cross, Coalition for Hemophilia B, Inc.
    Inventors: Shirley I. Miekka, William N. Drohan, Thomas R. Jameson, John R. Taylor, Jr., Manish S. Singh
  • Patent number: 6291424
    Abstract: Nitrosylation of proteins and amino acid groups enables selective regulation of protein function, and also endows the proteins and amino acids with additional smooth muscle relaxant and platelet inhibitory capabilities. Thus, the invention relates to novel compounds achieved by nitrosylation of protein thiols. Such compounds include: S-nitroso-t-PA, S-nitroso-cathepsin; S-nitroso-lipoprotein; and S-nitroso-immunoglobulin. The invention also relates to therapeutic use if S-nitroso-protein compounds for regulating protein function, cellular metabolism and effecting vasodilation, platelet inhibition, relaxation of non-vascular smooth muscle, and increasing blood oxygen transport by hemoglobin and myoglobin. The compounds are also used to deliver nitric oxide in its most bioactive form in order to achieve the effects described above, or for in vitro nitrosylation of molecules present in the body.
    Type: Grant
    Filed: June 5, 1998
    Date of Patent: September 18, 2001
    Assignee: Brigham and Women's Hospital
    Inventors: Johnathan Stamler, Joseph Loscalzo, David J. Singel
  • Patent number: 6284871
    Abstract: The present invention relates to biologically active peptides which specifically inhibit the Factor IX-dependent pathway of blood coagulation. These peptides are based on a specific motif which represents a sequence of Factor VIII (amino acid 1811-1818) involved in binding to activated Factor IX as well as to the intact Factor IX zymogen. Binding of said peptides to Factor IX or activated derivatives thereof effectively inhibits complex assembly with Factor VIII. These peptides thereby specifically interfere in the Factor IX-dependent pathway of thrombin formation, while leaving other haemostatic pathways unaffected. By virtue of this unique specificity, the peptides of this invention are particularly useful in novel pharmaceutical compositions for the treatment of thrombotic disorders.
    Type: Grant
    Filed: December 9, 1997
    Date of Patent: September 4, 2001
    Assignee: Stiching Centraal Laboratorium van de Bloedtransfusiedienst van Nederlandse Rode Kruis
    Inventors: Koenraad Mertens, Petrus Johannes Lenting
  • Patent number: 6242418
    Abstract: Methods and materials for the treatment of human meningococcemia are provided in which therapeutically effective amounts of BPI protein products are administered.
    Type: Grant
    Filed: August 3, 1999
    Date of Patent: June 5, 2001
    Assignees: Xoma Corporation, The Board of Regents, The University of Texas System
    Inventors: Brett P. Giroir, Patrick J. Scannon
  • Patent number: 6197745
    Abstract: S-nitrosothiols (RSNOs) can donate the NO group to the &bgr;93 cysteine residues of hemoglobin (Hb) without inactivating the heme. S-nitrosylation of Hb is under the allosteric control of oxygen and the oxidation state of heme. NO group release from S-nitrosohemoglobin (SNO-Hb) is further facilitated by intracellular low molecular weight thiols, forming RSNOs which can be exported from the erythrocyte to regulate blood pressure and platelet activation. SNO-Hb can be formed by reaction of Hb with S-nitrosothiol. This procedure avoids oxidation of the heme. Other methods can be used which are not specific only for thiol groups, but which nitrosate Hb more extensively, and may produce polynitrosated metHb as a product or intermediate product of the method.
    Type: Grant
    Filed: June 20, 1996
    Date of Patent: March 6, 2001
    Assignee: Duke University
    Inventor: Jonathan S. Stamler
  • Patent number: 6150331
    Abstract: Provided is an aqueous pharmaceutical composition comprising human growth hormone wherein said human growth hormone is dissolved in a benzalkonium chloride-containing, slightly to weakly acidic solution buffered, most preferably, with maleate. The composition is sufficiently stable to be supplied in liquid state and can be prepared as a less painful composition.
    Type: Grant
    Filed: December 18, 1998
    Date of Patent: November 21, 2000
    Assignee: JCR Pharmaceuticals Co., Ltd.
    Inventors: Masafumi Tatsumi, Katsura Inoue, Junichi Kajihara
  • Patent number: 6143867
    Abstract: The present invention provides a human eosinophil-derived basic protein (EBPH) and polynucleotides which identify and encode EBPH. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding EBPH and a method for producing EBPH. The invention also provides for use of EBPH and agonists, antibodies or antagonists specifically binding EBPH, in the prevention and treatment of diseases associated with expression of EBPH. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding EBPH for the treatment of diseases associated with the expression of EBPH. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding EBPH.
    Type: Grant
    Filed: March 17, 1998
    Date of Patent: November 7, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventor: Ingrid E. Akerblom
  • Patent number: 6132730
    Abstract: The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising coagulation-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutic drugs, targeted immunotoxins, targeted coaguligands, and/or in combination with Factor VIIa (FVIIa) or FVII activators.
    Type: Grant
    Filed: January 20, 1998
    Date of Patent: October 17, 2000
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip E. Thorpe, Steven W. King, Boning Gao
  • Patent number: RE38431
    Abstract: The present invention relates to the preparation and use of liquid formulations of plasma proteins, particularly blood coagulation factors. More specifically, the present invention relates to stable liquid formulations of Factor VIII and Factor IX that can be administered by injection or infusion to provide a constant level of the coagulation factor in the blood.
    Type: Grant
    Filed: August 26, 2002
    Date of Patent: February 17, 2004
    Assignees: The American National Red Cross, The Coalition for Hemophilia B
    Inventors: Shirley I. Miekka, William N. Drohan, Thomas R. Jameson, John R. Taylor, Jr., Manish P. Singh, Martin J. MacPhee